Moscow, Russia

Sergei D Maltsev

This inventor holds 1 USPTO granted patent. Top assignee: Sass & Sass, Inc.. Active years: 2003.


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sergei D Maltsev: Innovator in Therapeutic Compositions

Introduction

Sergei D Maltsev is a notable inventor based in Moscow, Russia. He has made significant contributions to the field of therapeutic compositions, particularly in the development of antiviral and immunomodulatory agents. His work is characterized by a focus on innovative solutions for treating various health conditions, including cancer.

Latest Patents

Maltsev holds a patent for a therapeutic composition that includes polyprenol monophosphates and polyprenol pyrophosphates. The invention provides a composition that is useful as an antiviral agent and for treating cancer. The patent outlines the specific formulas for these compounds, which are designed to enhance therapeutic efficacy.

Career Highlights

Sergei D Maltsev is associated with Sass & Sass, Inc., where he continues to advance his research and development efforts. His work has led to the creation of pharmaceutical compositions that leverage his patented inventions. Maltsev's dedication to innovation in the medical field has positioned him as a key figure in therapeutic research.

Collaborations

Maltsev has collaborated with notable colleagues, including Olga Y Sosnovskaya and Alexander N Narovlianskiy. These partnerships have contributed to the advancement of his research and the successful development of his patented compositions.

Conclusion

Sergei D Maltsev's contributions to therapeutic compositions highlight his role as an innovator in the medical field. His patented inventions demonstrate a commitment to improving health outcomes through advanced research and collaboration.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…